DOCSLIB.ORG

Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat in Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat in Breast Cancer Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat in Breast Cancer December 2, 2010 10:52 AM ET Telomerase Inhibitor in Combination with Chemotherapy Targets Cancer Stem Cells MENLO PARK, Calif., December 2, 2010 - Geron Corporation (Nasdaq: GERN) today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer. "We are pleased to initiate our second randomized Phase 2 clinical trial of imetelstat," said Stephen M. Kelsey, M.D., Geron's executive vice president and chief medical officer, oncology. "We are applying what we learned in our Phase 1 program and leveraging our preclinical data that showed imetelstat's activity against cancer stem cells from a broad range of tumor types, including breast cancer." "We look forward to assessing imetelstat in this Phase 2 clinical trial in breast cancer," said Kathy D. Miller, M.D., Associate Professor and Sheila D. Ward Scholar at the Indiana University Melvin and Bren Simon Cancer Center and lead investigator of the trial. "The Phase 1 trial of imetelstat combined with paclitaxel and bevacizumab in locally recurrent or metastatic breast cancer showed an encouraging preliminary response rate, particularly in context of the reduced doses of chemotherapy that were administered during treatment cycles." Phase 2 Trial Design The clinical trial is an open label, multi-center, randomized Phase 2 study of the efficacy and safety of treatment with imetelstat plus paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) for patients with locally recurrent or metastatic breast cancer (MBC) who have not received chemotherapy or have received one non-taxane based chemotherapy for MBC. The primary efficacy endpoint for this Phase 2 trial is to estimate progression-free survival (PFS) for patients receiving imetelstat in addition to paclitaxel with or without bevacizumab. Secondary efficacy endpoints are objective response rate and clinical benefit of imetelstat when added to paclitaxel with or without bevacizumab. Safety and tolerability will also be assessed. Patients eligible for the trial are randomly assigned in a 1:1 ratio to receive either imetelstat in addition to paclitaxel or paclitaxel only. Patients may receive bevacizumab based on the investigator's decision and drug availability to the patient, but bevacizumab therapy is not required. Patients in the trial will be stratified based on two parameters: (1) whether bevacizumab is used in combination with paclitaxel; and (2) line of therapy (first line versus second line). Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day treatment cycle. Paclitaxel is administered at 90 mg/m2 on days one and eight and bevacizumab is administered at 15 mg/kg on day one of the 21 day cycle. The dose and dosing schedule of imetelstat was established during the Phase 1 clinical trial of imetelstat in combination with paclitaxel and bevacizumab in locally advanced or MBC. Enrollment is estimated at 150 patients at approximately 80 clinical sites across the U.S. and Canada. Rationale for the Trial Results from Phase 1 clinical trials using imetelstat have documented imetelstat's safety profile. Data from preclinical studies have demonstrated imetelstat's activity against bulk breast cancer cells as well as breast cancer stem cells. The prior Phase 1 clinical trial testing the safety of imetelstat in combination with paclitaxel and bevacizumab in patients with locally recurrent or MBC showed an objective response rate of 53.8% (95% confidence interval: 28.7% to 77.6%) despite reduced doses of paclitaxel and/or imetelstat in the majority of patients. Median response duration was 21.7 weeks (7.3 to 48.3 weeks). These data provided the rationale for conducting the current Phase 2 study. The Phase 2 dose and dosing schedule of 300 mg/m2 of imetelstat on day one of a 21 day treatment cycle was selected to achieve extended exposures to imetelstat that exceed the levels that have been associated with efficacy in xenograft models of human cancers, while minimizing hematological toxicities. Page 1/3 In addition, previously published in vitro studies showed that imetelstat synergizes with paclitaxel in inhibiting the growth of breast cancer cells. Synergy between imetelstat and bevacizumab was demonstrated in a xenograft model of human breast cancer. Breast Cancer Stem Cells Cancer stem cells are rare populations of malignant cells with the capacity for endless self-renewal because of high telomerase activity. Cancer stem cells are believed to be responsible for tumor growth, recurrence and metastasis. Their resistance to chemotherapy and conventional anti-cancer agents make them important targets for novel therapies. By inhibiting breast cancer stem cells, the use of imetelstat in combination with standard debulking chemotherapy, such as paclitaxel, may result in a more durable tumor response than with chemotherapy alone. Breast cancer stem cell function was inhibited by imetelstat in preclinical models. Imetelstat treatment of breast cancer cells in vitro led to inhibition of self-renewal capacity and cell death. In animal models of human breast cancer, imetelstat treatment reduced the formation of new tumors by 50%. These data were published by Geron scientists and collaborators in the November 15, 2010 issue of Cancer Research. About Breast Cancer Breast cancer is the most frequent cancer affecting women worldwide and remains the leading cause of cancer death among women. In 2007, an estimated 1.3 million new cases of breast cancer were diagnosed and an estimated 468,000 breast cancer- related deaths occurred. The highest incidence of breast cancer is in the United States, where, in 2010, an estimated 207,090 new cases will be diagnosed in women and 1,940 in men, and an estimated 40,230 people will die of the disease (American Cancer Society, Cancer Facts and Figures 2010). About Telomerase and Imetelstat (GRN163L) Telomerase is a critical and broadly applicable tumor target. The enzyme is expressed in a wide range of malignant tumors, and its activity is essential for the indefinite replicative capacity of cancer that enables malignant cell growth. Telomerase has now also been shown to be a target of cancer stem cells. Telomerase is absent or expressed only transiently at low levels in most normal adult tissues. Imetelstat is a lipidated short chain oligonucleotide that binds with high affinity and specificity to the catalytic site of telomerase, resulting in competitive inhibition of enzyme activity. Proprietary manufacturing chemistry and the addition of a 5' lipid chain have enabled the molecule to penetrate cells and tissues throughout the body. Imetelstat has demonstrated anti-tumor effects in a wide range of preclinical xenograft models of human solid and hematological tumors, and potent activity against cancer stem cells derived from primary patient samples or cancer cell lines from multiple tumor types. Imetelstat has been tested in six Geron-sponsored Phase 1 clinical trials at 22 U.S. medical centers treating over 180 patients examining the safety, tolerability, pharmacokinetics and pharmacodynamics of the drug, alone or in combination with other standard therapies, in patients with different hematological and solid tumors. A randomized Phase 2 clinical trial of imetelstat has been initiated in non-small cell lung cancer. Two single arm Phase 2 clinical trials are planned in multiple myeloma and essential thrombocythemia. All are malignancies in which cancer stem cells are believed to play an important role in relapse after standard therapy. About Geron Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple Phase 2 clinical trials in different cancers. For more information about Geron, visit www.geron.com. This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding potential applications of Geron's telomerase and oncology technology constitute forward-looking statements that involve risks and uncertainties, including, Page 2/3 without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and protection of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended September 30, 2010 and quarterly report on Form 10-K for the year ended December 31, 2009. CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] # # # Page 3/3.
Load more

Recommended publications
  • GERON CORPORATION (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-20859 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 75-2287752 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 149 Commonwealth Drive, Suite 2070, Menlo Park, CA 94025 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (650) 473-7700 Securities registered pursuant to Section 12(b) of the Act: Title of each class: Trading symbol(s): Name of each exchange on which registered: Common Stock, $0.001 par value GERN The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Lengthened Telomeres Restore Immune System to a Younger State
    Dear friend, you are presumably here to find out more information on TA-65 telomeres and telomerase. This page contains just a small amount of what I have written about the topics but, many times the questions I get are the same. Here you will find the answers to many of the more frequently asked questions that I could not cover on the TA-65 page. Please note: I kept many of them in “post format” as they were originally published on the internet. Lengthened telomeres restore immune system to a younger state New study is the first ever Peer-Reviewed Report of a Telomerase Activator taken by live humans. New York, NY (September 8, 2010) — A pioneering study published in the Rejuvenation Research Journal today shows that TA-65, a natural Telomerase Activator made and marketed by Telomerase Activation Sciences, Inc. (“T.A. Sciences”), reduces the percentage of short telomeres in immune cells and restores and remodels the aging human immune system to be more like that of a younger individual. The year-long study of the first 100 clients of T.A. Sciences found that TA-65, a nutritional supplement marketed only through specialized doctors, had been successful in lengthening shortened telomeres. Telomeres are sequences of DNA, located at the ends of all chromosomes, which serve as cellular clocks of aging. Every time a cell divides, telomeres shorten until they become critically short, and the cell either stops functioning properly or dies. By activating a gene that is normally turned off, TA-65 has been shown to activate the enzyme telomerase.
    [Show full text]
  • Michael D. West (1953- ) [1]
    Published on The Embryo Project Encyclopedia (https://embryo.asu.edu) Michael D. West (1953- ) [1] By: Jiang, Lijing Keywords: Biography [2] Stem cells [3] Regeneration [4] Michael D. West is a biomedical entrepreneur and investigator whose aim has been to extend human longevity with biomedical interventions. His focus has ranged from the development of telomerase-based therapeutics to the application of human embryonic stem cells [5] in regenerative medicine [6]. Throughout his eventful career, West has pursued novel and sometimes provocative ideas in a fervent, self-publicizing manner. As of 2009, West advocated using human somatic cell nuclear transfer [7] techniques to derive human embryonic stem cells [5] for therapeutic practice. Through his testimonies before the US Senate, articles, and even controversies generated by his own research and claims, West has played an important role in shaping the public debate over human cloning [8] and embryonic stem cell research [9]. Born in Niles, Michigan, on 28 April 1953, West grew up in a wealthy family that ran a profitable automotive leasing business. West’s scientific predilection was discovered and cultivated early in his childhood, when he could enjoy a laboratory-like set-up in a storage area above the family’s garage. After entering Niles Senior High School, West became interested in a broad range of philosophical questions such as the meaning of life. These interests led him into an amateur but persistent study of philosophy, theology, mythology, and folklore for about ten years, during which he also managed to teach himself Greek and Hebrew. The intellectual development of West, although initiated somewhat precociously, took a most circuitous path.
    [Show full text]
  • Michael West CV
    MICHAEL DAVID WEST, B.S., M.S., Ph.D. CURRICULUM VITAE November, 2016 Summary: Dr. West is Co-Chief Executive Officer of BioTime, Inc. (NYSE MKT: BTX). BioTime and its subsidiaries are focused on developing an array of research and therapeutic products using pluripotent stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the founder and first CEO of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1992 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. In 2013 he led BioTime’s efforts to acquire Geron’s stem cell assets now residing in the BioTime subsidiary Asterias Biotherapeutics (NYSE MKT: AST). From 1998 to 2007 he held positions as CEO, President, and Chief Scientific Officer at Advanced Cell Technology, Inc., which was acquired by Astellas Pharma, Inc., where he managed programs in nuclear transfer, retinal differentiation, and PureStemTM, a technology for the multiplex derivation and characterization of diverse clonal human embryonic progenitor cell lines.
    [Show full text]
  • Geron Corporation
    GERON CORPORATION FORM 10-K (Annual Report) Filed 2/27/2004 For Period Ending 12/31/2003 Address 230 CONSTITUTION DRIVE MENLO PARK, California 94025 Telephone 650-473-7700 CIK 0000886744 Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2003 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to ____________ to __________. Commission File Number: 0-20859 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 75 -2287752 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 230 Constitution Drive, Menlo Park, CA 94025 (Address, including zip code, of principal executive offices) Registrant’s telephone number, including area code: (650) 473-7700 Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Common Stock $0.001 par value Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Activated Myeloproliferative Neoplasm and Leukemia Stem Cells
    Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1- activated Myeloproliferative Neoplasm and Leukemia Stem Cells Wenxue Ma1, Larisa Balaian1, Phoebe Mondala1, Yudou He1, Cayla Mason1, Jessica Pham1, Jeremy Lee1, Raymond Diep1, Sanja Coso1, Kathleen Fisch1, Adam Mark1, Sheldon Morris1, Qingfei Jiang1, Thomas Whisenant1, Aleksandra Rizo2, Fei Huang2, Mary Donohoe1, Ludmil Alexandrov1, and Catriona Jamieson1* 1 Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Clinical Center, University of California San Diego, La Jolla, CA; 2 Geron Corporation, Parsippany, NJ. *Corresponding author: Catriona Jamieson, MD PhD, Deputy Director, UC San Diego Moores Cancer Center and Director, Sanford Stem Cell Clinical Center, [email protected] Fig. 1 Telomere Shortening Characterizes Pre-LSC and LSC A B ●● ●● 100 R = - 0.46 , p = 0.003 100 R = - 0.47 , p = 0.0023 Wilcoxon, p = 0.041 Wilcoxon, p = 0.14 y = 97 - 0.092 x y = 98 - 0.11 x n n i i ● ● t t n n ● e e t ● ● t 15 n ● ● ● ● ● n s o ● ● o 80 ● ● 80 ● ● l l c c 10 ● ● ● e e e ● c s r ● ● ● ● r l ● ● l ● ● ● ● e ● ● e Sex ● Sex e ● ● ● ● m c m m ● ● e ● ● ● ● t o ● ● ●● o ● ● ● ● a l l ● ● ● s ● ● Female Female e e v e e g g i ● t t l ● ● + 10 A A ● ● ● ● ● ● a 4 Male Male d 60 60 d ● ● ● s 3 ● e e ● t ● ● t ● ● ● ● D ● c ● ● ● ● c ● ● C e e ● ● ● ● ● r r ● ● ● ● ● r ● ● r ● ● ● ● o ● ● o ● 5 ● ● c ● ● ● ● c ● ●● ● e ● ● e ● ● ● ● g g ● ● 40 40 ● ● ● ● 5 ● ● ● ●● ● ● ● A ● ● A ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● Female
    [Show full text]
  • Geron Corporation 2000 Annual Report
    ANNUAL REPORT 2000 Sometimes the body heals itself. Sometimes it does not. UNLIKE BONE, NEURONS DO NOT REGENERATE AFTER INJURY. IF A NERVE CELL IS DAMAGED DUE TO DISEASE OR INJURY, THERE IS NO TREATMENT AT PRESENT TO RESTORE LOST FUNCTION. GERON / 2000 Sometimes our cells fight disease. GERON / 2000 . Sometimes our cells are the disease. CANCER OCCURS WHEN CELLS BEGIN TO MULTIPLY EXCESSIVELY AS THE RESULT OF GENETIC MUTATIONS, CAUSING A TUMOR TO GROW UNCONTROLLABLY. TUMORS TURN ESPECIALLY DEADLY WHEN CANCER CELLS SPREAD THROUGHOUT THE BODY. GERON / 2000 How When Why Where Oncology FINDING AND FIGHTING CANCER Geron is leveraging the power of telomerase to develop novel ways of diagnosing and treating a broad range of cancers. An enzyme that confers replicative immortality to cells, telomerase is present in all cancer types studied to date, making it a universal and specific target for the development of a new class of cancer diagnostics and therapeutics. Regenerative Medicine REPAIRING DAMAGE, RESTORING FUNCTION Through the integration of its powerful and proprietary technology platforms, Geron intends to become the leader in the emerging field of regenerative medicine. The company’s goal is to produce tissue-matched, healthy and youthful replacement cells to restore organ function lost to disease. In this way, Geron expects to establish living cells as tomorrow’s pharmaceuticals. GERON / 2000 . GERON’S THREE TECHNOLOGY PLATFORMS SUPPORT MULTIPLE PRODUCT OPPORTUNITIES THAT ARE GROUPED BY TARGET MARKET INTO FOUR BUSINESS UNITS TO ACCELERATE PRODUCT DEVELOPMENT, PARTNERING AND COMMERCIALIZATION. Oncology Regenerative Medicine • Telomerase • Human Embryonic Stem Cells • Nuclear Transfer Predictive Nuclear Transfer: Toxicology and Screening Ag / Xeno / Biologics .
    [Show full text]
  • Geron Annual Report 2008
    GERON ANNUAL REPORT 2008 Dear Stockholders, The two principal goals for Geron Corporation in 2008 were to initiate the world’s first clinical trial of a human embryonic stem cell (hESC)-based therapy and to demonstrate utility of GRN163L, our telomerase inhibitor drug, in cancer patients. In last year’s annual report, we stated that accomplishing these two goals would complete our transition into a fully integrated clinical development company. I am pleased to report success on both fronts as detailed in the enclosed letters. Each product in clinical development is a proprietary, first-in-class therapy with substantial economic potential. We expect a very exciting 2009 as we advance our programs toward the demonstration of safety and clinical utility in patients. As always, we are grateful for your support. REGENERATIVE MEDICINE “ FDA clearance of our GRNOPC1 Investigational New Drug (IND) application is one of Geron’s most significant accomplishments to date. This marks the beginning of what is potentially a new chapter in medical therapeutics — one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells.” REGENERATIVE MEDICINE GRNOPC1 – Glial Cells fOR SPINAL CORD INJURY Geron Receives FDA Clearance to Begin World’s First Human Clinical Trial of Embryonic Stem Cell-Based Therapy In January of 2009, we received clearance from the U.S. Food and Drug Administration (FDA) to begin a clinical trial of GRNOCP1, our hESC-derived cell therapy for acute spinal cord injury. GRNOPC1 contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury (Journal of Neuroscience, Vol.
    [Show full text]
  • US Treats First Patient with Human Embryonic Stem Cells (Update 2) 11 October 2010, by Karin Zeitvogel
    US treats first patient with human embryonic stem cells (Update 2) 11 October 2010, by Karin Zeitvogel US doctors have begun the first tests of human Geron began working with human embryonic stem embryonic stem cells in patients, treating a man cells in 1999. with spinal cord injuries in a landmark trial of the controversial process, the Geron Corporation said Back then, "many predicted that it would be a Monday. number of decades before a cell therapy would be approved for human clinical trials," Geron's The patient began the pioneering treatment Friday president and chief executive Thomas Okarma said with an injection of the biotech company's human in a statement. embryonic stem cells, as part of a clinical trial that aims to test safety and efficacy toward regaining Okarma described Monday's start of the clinical trial sensation and movement. as "a milestone for the field of human embryonic stem cell-based therapies." The treatment took place at the Shepherd Center in Atlanta, Georgia, a spokeswoman for the GRNOPC1 is made up of cells containing hospital told AFP, declining to give further details precursors to oligodendrocytes -- multi-tasking cells due to patient privacy concerns. that occur in the nervous system. The Phase I trial is expected to involve around 10 Oligodendrocytes are lost in spinal cord injury, patients. Participants in the human trials must be resulting in myelin and neuronal loss which cause severely injured and start treatment with Geron's paralysis in many patients. product, GRNOPC1, seven to 14 days after sustaining their injury. Preclinical studies of GRNOPC1 found that when it was injected into the injury site of animals with Patients will be given a single injection of two spinal cord injuries, it migrated throughout the million of Geron's GRNOPC1 cells in the trial.
    [Show full text]
  • Geron Corporation 919 E
    GERON CORPORATION 919 E. Hillsdale Blvd., Suite 250 Foster City, CA 94404 April 14, 2020 Dear Fellow Geron Stockholder: You are cordially invited to attend the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of Geron Corporation to be held on Friday, June 5, 2020, at 8:00 a.m., Pacific Daylight Time. In light of the COVID-19 pandemic, for the safety of all our stockholders and personnel, and taking into account recent federal, state and local guidance that has been issued, we have determined that the Annual Meeting will be held in a virtual meeting format only, via the Internet, with no physical in-person meeting. You will be able to attend and participate in the virtual Annual Meeting online by visiting www.virtualshareholdermeeting.com/GERN2020, where you will be able to listen to the meeting live, submit questions, and vote. Instructions on how to participate in the virtual Annual Meeting and demonstrate proof of stock ownership are posted at www.virtualshareholdermeeting.com/GERN2020. The webcast of the virtual Annual Meeting will be archived for one year after the date of the virtual Annual Meeting at www.virtualshareholdermeeting.com/GERN2020. As permitted by the rules of the Securities and Exchange Commission, we are pleased to furnish our proxy materials to stockholders primarily over the Internet. Consequently, most stockholders will receive a notice with instructions for accessing proxy materials and voting via the Internet, instead of paper copies of proxy materials. However, this notice will provide information on how stockholders may obtain paper copies of proxy materials if they choose.
    [Show full text]
  • Geron Announces Presentation at ECTRIMS/ACTRIMS October 25, 2011 3:38 PM ET Non-Clinical Data Supports Use of GRNOPC1 in Multipl
    Geron Announces Presentation at ECTRIMS/ACTRIMS October 25, 2011 3:38 PM ET Non-Clinical Data Supports Use of GRNOPC1 in Multiple Sclerosis MENLO PARK, Calif., October 25, 2011 - Geron Corporation (Nasdaq: GERN) today announced data on the use of GRNOPC1, oligodendrocyte progenitors derived from human embryonic stem cells, for myelin repair in a non-human primate model. The data supports further investigation of the potential therapeutic use of GRNOPC1 in central nervous system (CNS) disorders where the central or contributing pathology is destructive removal of myelin from nerve axons, such as observed in multiple sclerosis (MS), myelitis and spinal cord injury. GRNOPC1 is currently in a Phase 1 clinical trial in patients with spinal cord injury. The new data were presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, in Amsterdam, by Prof. Jeffery D. Kocsis, Ph.D., from Yale University School of Medicine. The work was performed in collaboration with scientists at Geron. The studies utilized a non-human primate model where demyelinated lesions, such as seen in multiple sclerosis, were induced chemically in the spinal cord. GRNOPC1 was injected into the demyelinated spinal cord lesions one week after chemical induction. The lesion sites from six monkeys were analyzed using light and electron microscopy at various timepoints up to one year after injection of GRNOPC1 to look for evidence of cell survival and remyelination of nerve axons. In the first few weeks after implantation, the injection sites contained maturing transplanted cells indicative of a premyelinating phenotype with evidence of variable numbers and degrees of remyelinated axons.
    [Show full text]
  • Commercializing Stem Cell-Based Therapies: Meeting NIH and FDA Requirements by Kalah NIH Andfdarequirements Cell-Based Commercializing Stem a Uchincloss T Herapies
    September 2009 S EQUIREMENT R DA AND F Commercializing Stem NIH EETING Cell-Based Therapies: Meeting M : S NIH and FDA Requirements HERAPIE T Driving Business Advantage ED by Kalah Auchincloss S IALIZING STEM CELL-BA C COMMER COMMER In March, President Obama signed an executive order lifting the Bush C Administration restrictions on federal funding for human embryonic stem cell (HES) IALIZING STEM CELL-BA research. The possibility of new federal funding opportunities, in combination with more than a decade of scientific advances in both embryonic and adult stem cell research, signal that stem cell-based therapies (“SCBT”) could soon be available for patients in a clinical setting. For those wishing to commercialize such therapies, it will be important to ascertain how the U.S. Food and Drug Administration (“FDA”), S which has regulatory authority over U.S. marketing of SCBT, will exercise this ED oversight. T HERAPIE This article is not intended to be an exhaustive dissertation on all laws and 1 S regulations pertaining to stem cell research, embryonic or otherwise. Rather, it : M discusses the controversial history of federal funding for stem cell research, and EETING then focuses on regulations and guidelines likely to govern FDA approval of clinical applications of SCBT. It also discusses some of the recent recommendations NIH included in the International Society for Stem Cell Research Guidelines in the AND F context of U.S. application of those recommendations. DA R NIH: Restrictions on Federal Funding for Human EQUIREMENT Embryonic Stem Cell Research Federal funding for human embryonic stem cell research enjoys a long and storied S history, reflecting the moral, ethical, and political sensitivities of theU .S.
    [Show full text]